Definium Therapeutics Shares Jump on Strong Depression Drug Phase 3 Results

Dow Jones

Jun 22

By Adriano Marchese

Definium Therapeutics shares surged in premarket trading Monday after the company reported strong phase 3 results for its experimental depression treatment.

Shares traded 50% higher ahead of the morning bell at $36.74.

The late-stage clinical biopharmaceutical company said patients receiving DT120, also known as lysergide, showed an improvement on a standard depression scale at week six, with effects emerging as early as the first week and lasting for up to 12 weeks.

The Emerge study met its primary and all key secondary endpoints, including an eight-point placebo-adjusted reduction in symptoms by the sixth week.

"The Emerge topline results represent unprecedented and highly differentiated efficacy, demonstrating that a single dose of DT120 ODT can deliver rapid, robust, and durable relief in major depressive disorder," said Chief Executive Rob Barrow.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 22, 2026 08:42 ET (12:42 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2645217022"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645217022\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645217022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645217022","market":"other","top_or_hot":-1,"title":"Definium Therapeutics Shares Jump on Strong Depression Drug Phase 3 Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DFTX\">Definium Therapeutics</a> shares surged in premarket trading Monday after the company reported strong phase 3 results for its experimental depression treatment. \n</p>\n<p>\n  Shares traded 50% higher ahead of the morning bell at $36.74. \n</p>\n<p>\n  The late-stage clinical biopharmaceutical company said patients receiving DT120, also known as lysergide, showed an improvement on a standard depression scale at week six, with effects emerging as early as the first week and lasting for up to 12 weeks. \n</p>\n<p>\n  The Emerge study met its primary and all key secondary endpoints, including an eight-point placebo-adjusted reduction in symptoms by the sixth week. \n</p>\n<p>\n  \"The Emerge topline results represent unprecedented and highly differentiated efficacy, demonstrating that a single dose of DT120 ODT can deliver rapid, robust, and durable relief in major depressive disorder,\" said Chief Executive Rob Barrow. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 08:42 ET (12:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Definium Therapeutics Shares Jump on Strong Depression Drug Phase 3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDefinium Therapeutics Shares Jump on Strong Depression Drug Phase 3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-22 20:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DFTX\">Definium Therapeutics</a> shares surged in premarket trading Monday after the company reported strong phase 3 results for its experimental depression treatment. \n</p>\n<p>\n  Shares traded 50% higher ahead of the morning bell at $36.74. \n</p>\n<p>\n  The late-stage clinical biopharmaceutical company said patients receiving DT120, also known as lysergide, showed an improvement on a standard depression scale at week six, with effects emerging as early as the first week and lasting for up to 12 weeks. \n</p>\n<p>\n  The Emerge study met its primary and all key secondary endpoints, including an eight-point placebo-adjusted reduction in symptoms by the sixth week. \n</p>\n<p>\n  \"The Emerge topline results represent unprecedented and highly differentiated efficacy, demonstrating that a single dose of DT120 ODT can deliver rapid, robust, and durable relief in major depressive disorder,\" said Chief Executive Rob Barrow. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 08:42 ET (12:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFTX","symbol_name":"Definium Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645217022","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645217022","pubTimestamp":1782132120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Definium Therapeutics shares surged in premarket trading Monday after the company reported strong phase 3 results for its experimental depression treatment.Shares traded 50% higher ahead of the morning bell at $36.74.The late-stage clinical biopharmaceutical company said patients receiving DT120, also known as lysergide, showed an improvement on a standard depression scale at week six, with effects emerging as early as the first week and lasting for up to 12 weeks.The Emerge study met its primary and all key secondary endpoints, including an eight-point placebo-adjusted reduction in symptoms by the sixth week.\"The Emerge topline results represent unprecedented and highly differentiated efficacy, demonstrating that a single dose of DT120 ODT can deliver rapid, robust, and durable relief in major depressive disorder,\" said Chief Executive Rob Barrow.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFTX":"Definium Therapeutics","BK4007":"制药"},"translate_title":"Definium Therapeutics股价因抑郁症药物3期结果强劲而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFTX":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\nDefinium Therapeutics shares surged in premarket trading Monday after the company reported strong phase 3 results for its experimental depression treatment. \n\n\n  Shares traded 50% higher ahead of the morning bell at $36.74. \n\n\n  The late-stage clinical biopharmaceutical company said patients receiving DT120, also known as lysergide, showed an improvement on a standard depression scale at week six, with effects emerging as early as the first week and lasting for up to 12 weeks. \n\n\n  The Emerge study met its primary and all key secondary endpoints, including an eight-point placebo-adjusted reduction in symptoms by the sixth week. \n\n\n  \"The Emerge topline results represent unprecedented and highly differentiated efficacy, demonstrating that a single dose of DT120 ODT can deliver rapid, robust, and durable relief in major depressive disorder,\" said Chief Executive Rob Barrow. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 08:42 ET (12:42 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}